Studies that evaluated the efficacy and safety of Vectibix® in the 1st line setting

Patients with wild-type RAS mCRC

PRIME1
(phase 3 trial)
PEAK2
(phase 2 trial)

Analysis

Prospective-retrospective

Prospective-retrospective

Patients with
wild-type RAS mCRC

512

170

Treatments

Vectibix® + FOLFOX vs

FOLFOX

Vectibix® + FOLFOX vs

bevacizumab + FOLFOX

Endpoints

PFS, OS, safety

PFS, OS,

Patients with wild-type RAS mCRC

PRIME1
(phase 3 trial)

Analysis

Prospective-retrospective

Patients with
wild-type RAS mCRC

512

Treatments

Vectibix® + FOLFOX vs

FOLFOX

Endpoints

PFS, OS

PEAK2
(phase 2 trial)

Analysis

Prospective-retrospective

Patients with
wild-type RAS mCRC

170

Treatments

Vectibix® + FOLFOX vs

bevacizumab + FOLFOX

Endpoints

PFS, OSORR, safety

References:

  1. Douillard J-Y et al. N Engl J Med 2013;369(11):1023–34.
    http://www .ncbi.nlm.nih.gov/pubmed/ 24024839 [last accessed September 2017].
  2. Rivera F et al. Int J Colorectal Dis 2017;32(8):1179-90. https://www.ncbi.nlm.nih.gov/ pubmed/ 28424871. [last accessed September 2017].
  3. Peeters M et al. Clin Cancer Res 2015;21(24):5469-79.
  4. Patterson SD et al. J Clin Oncol 2013;31(Suppl):3617 (abstract and poster presentation).